Overview
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Status:
Completed
Completed
Trial end date:
2016-12-22
2016-12-22
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
CelgeneTreatments:
Interferon beta-1a
Interferon-beta
Interferons
Ozanimod
Criteria
Inclusion Criteria:- Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria
- EDSS score between 0 and 5.0 at baseline
Exclusion Criteria:
• Primary progressive multiple sclerosis